SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 4

Left atrial appendage closure using Amulet device in a patient with prior percutaneous atrial septal defect closure

Daha önce perkütan yolla atriyal septal defekti kapatılan hastada sol atriyal apendiksin Amulet cihazı ile kapatılması

Kudret Aytemir
Uğur Canpolat
Cem Çöteli
Ergün Barış Kaya
Mehmet Levent Şahiner
Pages
306–308
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Paul, MN, USA) in a patientwith a previous history of percutaneous ASD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Percutaneous left atrial appendage (LAA) occlusion is an alternative therapeutic option for stroke prevention in patients with atrial fibrillation and contraindications for oral anticoagulation.
📊
Key Findings & Data:There are few data availableregarding the technical success of percutaneous LAA closure in patients with the previous implantation of an atrialseptal defect (ASD) or a patent foramen ovale closure device.
💡
Conclusion & Impact:Paul, MN, USA) in a patientwith a previous history of percutaneous ASD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Percutaneous left atrial appendage (LAA) occlusion is an alternative therapeutic option for stroke prevention in patients with atrial fibrillation and contraindications for oral anticoagulation. There are few data availableregarding the technical success of percutaneous LAA closure in patients with the previous implantation of an atrialseptal defect (ASD) or a patent foramen ovale closure device. This is the description of a case of a successful LAAclosure performed with an Amplatzer Amulet occluder device (St. Jude Medical, Inc., St. Paul, MN, USA) in a patientwith a previous history of percutaneous ASD.

Özet

Perkütan sol atriyal apendiks (SAA) kapatılması atriyal fibrilasyonu (AF) ve oral antikoagulasyona kontra-endikasyonu bulunan hastalarda inmenin önlenmesinde alternative bir tedavi şeklidir. Ancak daha önce perkütan atriyal septal defekt (ASD) ya da patent foramen ovale (PFO) kapama cihazı konulan hastalarda perkütan SAA kapatılmasının teknik açıdan başarısı ile ilgili çok az bilgi vardır. Bu nedenle, bu olguda daha önce perkütan ASD kapama işlemi yapılan hastada Amplatzer™ Amulet™ kapama cihazı (St. Jude Medical) kullanılarak perkütan yolla başarılı SAA kapama işlemi sunulmuştur.

🔖

Cite This Article

Aytemir, K., Canpolat, U., Çöteli, C., Kaya, E. B., Şahiner, M. L. (2022). Left atrial appendage closure using Amulet device in a patient with prior percutaneous atrial septal defect closure. Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 4, 306–308. https://ajindex.com/articles/632182

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78. [CrossRef] 2. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al; PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017;70:2964–75. [CrossRef] 3. De Backer O, Arnous S, Ihlemann N, Vejlstrup N, Jørgensen E, Pehrson S, et al. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart 2014;1:e000020. [CrossRef] 4. Heersink D, Murdoch D, Humphries J, Walters DL. Left Atrial Appendage Closure Device Implantation After Percutaneous Atrial Septal Defect Closure. JACC Cardiovasc Interv 2016;9:e95–6. [CrossRef] 5. Gafoor S, Franke J, Boehm P, Lam S, Bertog S, Vaskelyte L, et al. Leaving no hole unclosed: left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect. J Interv Cardiol 2014;27:414–22. [CrossRef] 6. Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke 2016;47:441–9. [CrossRef] 7. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175:18–24. [CrossRef] 8. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol 2015;66:2271–81. 9. Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiol 2015;115:533–41. [CrossRef] 10. Lin AC, Knight BP. Left atrial appendage closure. Prog Cardiovasc Dis 2015;58:195–201. [CrossRef] 11. Iskandar S, Vacek J, Lavu M, Lakkireddy D. Left Atrial Appendage Closure for Stroke Prevention: Devices, Techniques, and Efficacy. Cardiol Clin 2016;34:329–51. [CrossRef] 12. Gloekler S, Shakir S, Meier B. Transseptal Puncture Through Amplatzer Atrial Septal Occluder for Left Atrial Appendage Closure. JACC Cardiovasc Interv 2017;10:2222–3. [CrossRef]